Bos Sci launches MultiSENSE trial to test CRT-D monitoring
Boston Scientific has enrolled the first patient in its MultiSENSE clinical trial which is designed to evaluate multiple physiologic sensors in its Cognis cardiac resynchronization therapy defibrillators (CRT-Ds).
The Natick, Mass.-based company said it plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure. The first patient was enrolled by Paul Coffeen, MD, at Austin Heart in Austin, Texas, where Jeffrey Whitehill, MD, medical chair of the electrophysiology department, is the site's principal investigator.
When combined with its Latitude patient management system, Boston Scientific said its CRT-D sensors should be able to monitor a patient outside of a clinical setting and permit the Latitude system to deliver early notification to the physician when the patient's heart failure worsens.
The Natick, Mass.-based company said it plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure. The first patient was enrolled by Paul Coffeen, MD, at Austin Heart in Austin, Texas, where Jeffrey Whitehill, MD, medical chair of the electrophysiology department, is the site's principal investigator.
When combined with its Latitude patient management system, Boston Scientific said its CRT-D sensors should be able to monitor a patient outside of a clinical setting and permit the Latitude system to deliver early notification to the physician when the patient's heart failure worsens.